97精品国产品国语在线不卡,狠狠噜天天噜日日噜无码,超碰97人人做人人爱可以下载,国内精品久久久久影院蜜芽,亚洲AV无一区二区三区,精品一区二区三区无码免费视频,婷婷综合另类小说色区

About Us

DM Intelligence

DM Intelligence is an artificial intelligence development company that built AI solutions for small molecule drugs with high specific and affinity. Our proprietary platform, Artificial Intelligence Drug Discovery Platform (AI-DDP), integrates artificial intelligence technologies into the medical field to provide better service to pharmaceutical companies, academic centers and biotech companies.

AI-DDP allow us to optimize leads with specific desired properties as well as design small molecules targeting specific site or receptor. Our platform has extensive capabilities of analyzing and predicting physicochemical properties, biological and toxicological activities of candidate drugs based on their structures. With all these techniques, we strive for break thoughts in the future of drug discovery and research.

Products

Hit Identification

Discovering a new drug is more challenge and difficult. Hit identification is the first step for a successful drug discovery project. Manual screening and high-throughput screening become cumbersome and expensive, which identify one or few compounds from hundreds, thousands or even millions of compounds with the ability to inhibit the activity of targets. We develop innovative solutions to this problem: using molecular geometry model and energy model based on structural information to predict molecule-protein interactions and identify right, validated and high-quality hits.

Predictive Models

The quality of the candidate is the key determinant of a successful outcome of drug discovery programmes. Carrying out prediction studies prior to clinical development, such as analyzing and predicting physicochemical properties, biological and toxicological activities of candidate drugs may help in reducing workload, saving time, improving efficiency.

Founder/CEO WeiDong Xie

PhD. Imperial College London.

Professor, Sun Yat-sen University

Director, St. Jude Children's Research Hospital

CTO, CK Life Science Group

CEO Lindan Biotech, Canada.

VP Biotherapy Inc

Dr. RiQiang Deng

Professor, Sun Yat-sen University

Bioinformatics scientist IT, and AI, deep learning, neural network.

Dr. Da-Wei Gu

PhD. Imperial College London

Professor in Engineering, University of Leicester

Research interests include robust control, optimal control, optimization algorithms.

Chartered Engineer

a Fellow of IET

Dr.PingHua Sun

At present, he is the head of Department of pharmacy, School of pharmacy, Jinan University

Master of pharmaceutical chemistry, Shenyang Pharmaceutical University
Doctor of Biomedical Engineering, Jinan University
University of South Florida School of Medicine / Moffitt Cancer Institute postdoctoral

College of pharmacy,Jinan University:Assistant(2002-2004)
College of pharmacy,Jinan University:lecturer(2004-2010)
College of pharmacy,Jinan University:associate professor/Master Tutor(2010-2015)
College of pharmacy,Jinan University:professor/Doctoral supervisor(2015-Now)